Barry R. Davies

6.9k total citations
99 papers, 3.4k citations indexed

About

Barry R. Davies is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Barry R. Davies has authored 99 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Molecular Biology, 28 papers in Oncology and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Barry R. Davies's work include PI3K/AKT/mTOR signaling in cancer (26 papers), Prostate Cancer Treatment and Research (18 papers) and Cancer, Hypoxia, and Metabolism (9 papers). Barry R. Davies is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (26 papers), Prostate Cancer Treatment and Research (18 papers) and Cancer, Hypoxia, and Metabolism (9 papers). Barry R. Davies collaborates with scholars based in United Kingdom, United States and Japan. Barry R. Davies's co-authors include Philip S. Rudland, Roger Barraclough, Armelle Logié, Paul D. Smith, Michael P.A. Davies, Claire Crafter, Fiona E. M. Gibbs, Richard J. Edmondson, Richard O. Jenkins and Paul Martin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Barry R. Davies

98 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barry R. Davies United Kingdom	33	2.1k	1.0k	735	584	424	99	3.4k
Makoto Saegusa Japan	38	1.8k 0.9×	1.3k 1.3×	565 0.8×	680 1.2×	460 1.1×	163	3.8k
David J. Mulholland United States	28	2.9k 1.3×	1.2k 1.2×	1.2k 1.7×	937 1.6×	329 0.8×	50	4.4k
John F. Lyons United States	32	2.7k 1.3×	1.3k 1.3×	454 0.6×	551 0.9×	347 0.8×	81	4.3k
Janice A. Royds United Kingdom	35	2.1k 1.0×	1.4k 1.4×	469 0.6×	682 1.2×	369 0.9×	100	3.7k
Yoon‐La Choi South Korea	35	1.4k 0.7×	1.6k 1.6×	930 1.3×	1.1k 1.9×	342 0.8×	125	3.7k
Maria Rita Nicotra Italy	42	2.3k 1.1×	1.3k 1.3×	412 0.6×	577 1.0×	802 1.9×	79	4.3k
Peter Blume‐Jensen United States	18	3.3k 1.5×	1.3k 1.3×	561 0.8×	454 0.8×	840 2.0×	25	5.0k
E. Aubrey Thompson United States	42	3.3k 1.5×	1.6k 1.6×	486 0.7×	1.2k 2.1×	504 1.2×	112	5.0k
Hans Morreau Netherlands	33	1.7k 0.8×	1.5k 1.5×	455 0.6×	835 1.4×	651 1.5×	77	3.9k
Jeremy Chien United States	39	2.9k 1.4×	824 0.8×	344 0.5×	943 1.6×	326 0.8×	115	4.6k

Countries citing papers authored by Barry R. Davies

Since Specialization

Citations

This map shows the geographic impact of Barry R. Davies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry R. Davies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry R. Davies more than expected).

Fields of papers citing papers by Barry R. Davies

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry R. Davies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry R. Davies. The network helps show where Barry R. Davies may publish in the future.

Co-authorship network of co-authors of Barry R. Davies

This figure shows the co-authorship network connecting the top 25 collaborators of Barry R. Davies. A scholar is included among the top collaborators of Barry R. Davies based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry R. Davies. Barry R. Davies is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldberg, Frederick W., Attilla Ting, David T. Beattie, et al.. (2022). Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK. ACS Medicinal Chemistry Letters. 13(8). 1295–1301. 7 indexed citations

Nakamura, Kyoko, Ankur Karmokar, Paul Farrington, et al.. (2021). Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control. Clinical Cancer Research. 27(15). 4353–4366. 43 indexed citations

Jiang, Yanyan, Jennifer Martin, Paul Kinchesh, et al.. (2021). Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model. British Journal of Cancer. 124(11). 1809–1819. 4 indexed citations

Goldberg, Frederick W., M. Raymond V. Finlay, Attilla Ting, et al.. (2019). The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. Journal of Medicinal Chemistry. 63(7). 3461–3471. 66 indexed citations

Delpuech, Oona, Claire Rooney, Lorraine Mooney, et al.. (2016). Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547. Molecular Cancer Therapeutics. 15(11). 2802–2813. 18 indexed citations

Velasco, Marco A. De, et al.. (2016). Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN -deficient prostate cancer. Oncotarget. 7(13). 15959–15976. 22 indexed citations

Crafter, Claire, John P. Vincent, Eric Tang, et al.. (2015). Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models. International Journal of Oncology. 47(2). 446–454. 31 indexed citations

Ribas, Ricardo, Sunil Pancholi, Stephanie K. Guest, et al.. (2015). AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo. Molecular Cancer Therapeutics. 14(9). 2035–2048. 49 indexed citations

Davies, Barry R., Armelle Logié, Claire Crafter, et al.. (2015). Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Molecular Cancer Therapeutics. 14(11). 2441–2451. 54 indexed citations

10.

Guichard, Sylvie M., Jon Curwen, Teeru Bihani, et al.. (2015). AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. Molecular Cancer Therapeutics. 14(11). 2508–2518. 103 indexed citations

11.

Thomas, Christian, François Lamoureux, Claire Crafter, et al.. (2013). Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo. Molecular Cancer Therapeutics. 12(11). 2342–2355. 115 indexed citations

12.

Holt, Sarah V., Armelle Logié, Barry R. Davies, et al.. (2012). Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055). Cancer Research. 72(7). 1804–1813. 70 indexed citations

13.

Lamoureux, François, Christian Thomas, Claire Crafter, et al.. (2012). Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363. Clinical Cancer Research. 19(4). 833–844. 89 indexed citations

14.

Wilkinson, Robert W., Armelle Logié, Nicola J. Curtis, et al.. (2008). Activity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in combination with standard and approved therapies: impact of in vivo sequencing of drug administration. Cancer Research. 68. 4012–4012. 1 indexed citations

15.

Dovedi, Simon J., John A. Kirby, Barry R. Davies, Hing Y. Leung, & John D. Kelly. (2008). Celecoxib has Potent Antitumour Effects as a Single Agent and in Combination with BCG Immunotherapy in a Model of Urothelial Cell Carcinoma. European Urology. 54(3). 621–630. 32 indexed citations

16.

Davies, Barry R., Armelle Logié, Jennifer S. McKay, et al.. (2007). AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Molecular Cancer Therapeutics. 6(8). 2209–2219. 322 indexed citations

17.

BouHaidar, Ralph, et al.. (2004). Galectin‐3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology. 45(5). 493–500. 79 indexed citations

18.

Davies, Barry R., Angela Platt‐Higgins, Günter Schmidt, & Philip S. Rudland. (1999). Development of Hyperplasias, Preneoplasias, and Mammary Tumors in MMTV-c-erbB-2 and MMTV-TGFα Transgenic Rats. American Journal Of Pathology. 155(1). 303–314. 27 indexed citations

19.

Davies, Barry R., Nelly Auersperg, Sally Worsley, & B. A. J. Ponder. (1998). Transfection of rat ovarian surface epithelium with erb-B2/neu induces transformed phenotypes in vitro and the tumorigenic phenotype in vivo.. PubMed. 152(1). 297–306. 17 indexed citations

20.

McLeod, W. R., B J Carroll, & Barry R. Davies. (1970). Hypothalamic Dysfunction and Antidepressant Drugs. BMJ. 2(5707). 480.5–481. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact